1
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: an update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
3
|
Kaiser U, Schardt C, Brandscheidt D,
Wollmer E and Havemann K: Expression of insulin-like growth factor
receptors I and II in normal human lung and in lung cancer. J
Cancer Res Clin Oncol. 119:665–668. 1993. View Article : Google Scholar : PubMed/NCBI
|
4
|
Parker AS, Cheville JC, Janney CA and
Cerhan JR: High expression levels of insulin-like growth factor-I
receptor predict poor survival among women with clear-cell renal
cell carcinomas. Hum Pathol. 33:801–805. 2002. View Article : Google Scholar : PubMed/NCBI
|
5
|
Pekonen F, Nyman T, Ilvesmaki V and
Partanen S: Insulin-like growth factor binding proteins in human
breast cancer tissue. Cancer Res. 52:5204–5207. 1992.PubMed/NCBI
|
6
|
Resnik JL, Reichart DB, Huey K, Webster NJ
and Seely BL: Elevated insulin-like growth factor I receptor
autophosphorylation and kinase activity in human breast cancer.
Cancer Res. 58:1159–1164. 1998.PubMed/NCBI
|
7
|
Steller MA, Delgado CH, Bartels CJ,
Woodworth CD and Zou Z: Overexpression of the insulin-like growth
factor-1 receptor and autocrine stimulation in human cervical
cancer cells. Cancer Res. 56:1761–1765. 1996.PubMed/NCBI
|
8
|
Werner H, Re GG, Drummond IA, et al:
Increased expression of the insulin-like growth factor I receptor
gene, IGF1R, in Wilms tumor is correlated with modulation of
IGF1R promoter activity by the WT1 Wilms tumor gene
product. Proc Natl Acad Sci USA. 90:5828–5832. 1993. View Article : Google Scholar : PubMed/NCBI
|
9
|
Breuhahn K and Schirmacher P: Reactivation
of the insulin-like growth factor-II signaling pathway in human
hepatocellular carcinoma. World J Gastroenterol. 14:1690–1698.
2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chan JM, Stampfer MJ, Giovannucci E, et
al: Plasma insulin-like growth factor-I and prostate cancer risk: a
prospective study. Science. 279:563–566. 1998. View Article : Google Scholar : PubMed/NCBI
|
11
|
Vadgama JV, Wu Y, Datta G, Khan H and
Chillar R: Plasma insulin-like growth factor-I and serum
IGF-binding protein 3 can be associated with the progression of
breast cancer, and predict the risk of recurrence and the
probability of survival in African-American and Hispanic women.
Oncology. 57:330–340. 1999. View Article : Google Scholar : PubMed/NCBI
|
12
|
Boulle N, Logie A, Gicquel C, Perin L and
Le Bouc Y: Increased levels of insulin-like growth factor II
(IGF-II) and IGF-binding protein-2 are associated with malignancy
in sporadic adrenocortical tumors. J Clin Endocrinol Metab.
83:1713–1720. 1998.PubMed/NCBI
|
13
|
Martin DM, Singleton JR, Meghani MA and
Feldman EL: IGF receptor function and regulation in autocrine human
neuroblastoma cell growth. Regul Pept. 48:225–232. 1993. View Article : Google Scholar : PubMed/NCBI
|
14
|
Reeve AE, Eccles MR, Wilkins RJ, Bell GI
and Millow LJ: Expression of insulin-like growth factor-II
transcripts in Wilms’ tumour. Nature. 317:258–260. 1985.
|
15
|
Sohda T, Iwata K, Soejima H, Kamimura S,
Shijo H and Yun K: In situ detection of insulin-like growth factor
II (IGF2) and H19 gene expression in hepatocellular
carcinoma. J Hum Genet. 43:49–53. 1998. View Article : Google Scholar : PubMed/NCBI
|
16
|
Takeda S, Kondo M, Kumada T, et al:
Allelic-expression imbalance of the insulin-like growth factor 2
gene in hepatocellular carcinoma and underlying disease. Oncogene.
12:1589–1592. 1996.PubMed/NCBI
|
17
|
Zhang L, Zhou W, Velculescu VE, et al:
Gene expression profiles in normal and cancer cells. Science.
276:1268–1272. 1997. View Article : Google Scholar : PubMed/NCBI
|
18
|
Breuhahn K, Longerich T and Schirmacher P:
Dysregulation of growth factor signaling in human hepatocellular
carcinoma. Oncogene. 25:3787–3800. 2006. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wilkin F, Gagne N, Paquette J, Oligny LL
and Deal C: Pediatric adrenocortical tumors: molecular events
leading to insulin-like growth factor II gene overexpression. J
Clin Endocrinol Metab. 85:2048–2056. 2000.PubMed/NCBI
|
20
|
Denley A, Brierley GV, Carroll JM, et al:
Differential activation of insulin receptor isoforms by
insulin-like growth factors is determined by the C domain.
Endocrinology. 147:1029–1036. 2006. View Article : Google Scholar : PubMed/NCBI
|
21
|
Adams TE, Epa VC, Garrett TP and Ward CW:
Structure and function of the type 1 insulin-like growth factor
receptor. Cell Mol Life Sci. 57:1050–1093. 2000. View Article : Google Scholar : PubMed/NCBI
|
22
|
Perer ES, Madan AK, Shurin A, et al:
Insulin-like growth factor I receptor antagonism augments response
to chemoradiation therapy in colon cancer cells. J Surg Res.
94:1–5. 2000. View Article : Google Scholar : PubMed/NCBI
|
23
|
Burtrum D, Zhu Z, Lu D, et al: A fully
human monoclonal antibody to the insulin-like growth factor I
receptor blocks ligand-dependent signaling and inhibits human tumor
growth in vivo. Cancer Res. 63:8912–8921. 2003.PubMed/NCBI
|
24
|
Heron-Milhavet L, Karas M, Goldsmith CM,
Baum BJ and LeRoith D: Insulin-like growth factor-I (IGF-I)
receptor activation rescues UV-damaged cells through a p38
signaling pathway. Potential role of the IGF-I receptor in DNA
repair. J Biol Chem. 276:18185–18192. 2001. View Article : Google Scholar : PubMed/NCBI
|
25
|
Kulik G, Klippel A and Weber MJ:
Antiapoptotic signalling by the insulin-like growth factor I
receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol.
17:1595–1606. 1997.PubMed/NCBI
|
26
|
Jacobs S, Cook S, Svoboda ME and van Wyk
JJ: Interaction of the monoclonal antibodies αIR-1 and
αIR-3 with insulin and somatomedin-C receptors.
Endocrinology. 118:223–226. 1986.PubMed/NCBI
|
27
|
Sachdev D, Li SL, Hartell JS,
Fujita-Yamaguchi Y, Miller JS and Yee D: A chimeric humanized
single-chain antibody against the type I insulin-like growth factor
(IGF) receptor renders breast cancer cells refractory to the
mitogenic effects of IGF-I. Cancer Res. 63:627–635. 2003.
|
28
|
Cohen BD, Baker DA, Soderstrom C, et al:
Combination therapy enhances the inhibition of tumor growth with
the fully human anti-type 1 insulin-like growth factor receptor
monoclonal antibody CP-751,871. Clin Cancer Res. 11:2063–2073.
2005. View Article : Google Scholar
|
29
|
Lu D, Zhang H, Koo H, et al: A fully human
recombinant IgG-like bispecific antibody to both the epidermal
growth factor receptor and the insulin-like growth factor receptor
for enhanced antitumor activity. J Biol Chem. 280:19665–19672.
2005. View Article : Google Scholar : PubMed/NCBI
|
30
|
Langone JJ: Applications of immobilized
protein A in immunochemical techniques. J Immunol Methods.
55:277–296. 1982. View Article : Google Scholar : PubMed/NCBI
|
31
|
Pandini G, Vigneri R, Costantino A, et al:
Insulin and insulin-like growth factor-I (IGF-I) receptor
overexpression in breast cancers leads to insulin/IGF-I hybrid
receptor overexpression: evidence for a second mechanism of IGF-I
signaling. Clin Cancer Res. 5:1935–1944. 1999.
|
32
|
Scharf JG and Braulke T: The role of the
IGF axis in hepatocarcinogenesis. Horm Metab Res. 35:685–693. 2003.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Benini S, Manara MC, Baldini N, et al:
Inhibition of insulin-like growth factor I receptor increases the
antitumor activity of doxorubicin and vincristine against Ewing’s
sarcoma cells. Clin Cancer Res. 7:1790–1797. 2001.PubMed/NCBI
|
34
|
Gooch JL, Tang Y, Ricono JM and Abboud HE:
Insulin-like growth factor-I induces renal cell hypertrophy via a
calcineurin-dependent mechanism. J Biol Chem. 276:42492–42500.
2001. View Article : Google Scholar : PubMed/NCBI
|
35
|
Turner BC, Haffty BG, Narayanan L, et al:
Insulin-like growth factor-I receptor overexpression mediates
cellular radioresistance and local breast cancer recurrence after
lumpectomy and radiation. Cancer Res. 57:3079–3083. 1997.
|
36
|
Nakamura S, Watanabe H, Miura M and Sasaki
T: Effect of the insulin-like growth factor I receptor on ionizing
radiation-induced cell death in mouse embryo fibroblasts. Exp Cell
Res. 235:287–294. 1997. View Article : Google Scholar : PubMed/NCBI
|
37
|
Sell C, Baserga R and Rubin R:
Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent
etoposide-induced apoptosis. Cancer Res. 55:303–306.
1995.PubMed/NCBI
|
38
|
Dunn SE, Hardman RA, Kari FW and Barrett
JC: Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of
HBL100 human breast cancer cells by inhibition of apoptosis induced
by diverse anticancer drugs. Cancer Res. 57:2687–2693.
1997.PubMed/NCBI
|